about
Anti-angiogenesis and metastasis: a tumour and stromal cell allianceThe IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancerHypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.Side population and cancer stem cells: therapeutic implications.The angiogenic switch: implications in the regulation of tumor dormancy.Antiangiogenic therapies: going beyond their limits.Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model.Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy.Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy.The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors.Notch3 signalling promotes tumour growth in colorectal cancer.Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition.Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer.DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells
P50
Q26862741-C891CCE6-2106-422D-9CAA-DAB33BFC63D3Q34327974-C9245FE6-A1BC-42C0-9839-2A5BA9A3AE2FQ36037962-8F2D041C-160A-464A-98E5-05CE4C61368EQ36891578-9E628F27-C01F-4039-A31C-F48EE212CD8BQ37518176-96685C4D-B84F-4D0B-B0CC-60672086C3BEQ37635212-CCC49F2E-93AA-4BEC-88C3-2C67FC590FAFQ38172781-5273F20E-36C1-44CD-98A2-B2DF232BCB98Q39179249-2F1149EA-6BFA-4447-8F51-AB99E36AD459Q39547351-9C1F0757-4039-496A-BE36-F3C878834B18Q39669569-B1F19D8F-D1D7-4371-BE3E-4AA271C6FBDAQ39824358-4E974EE6-AC02-43F1-96FA-6A8EF2792814Q39885083-10ABCC6D-CC88-42E0-9CE1-D9873952769CQ39960772-3C8EE070-EAE2-4B0C-8894-C3F465D96588Q40270449-F4110ED9-EFEE-4D39-99C2-4E24AF6B5A33Q40309654-49861CEF-B7EC-4B88-829E-F21E14BA6950Q44547814-12D4EB0B-05C9-4A57-9318-C8AC76AFE1D1Q45885618-5332DF06-2022-4892-9AE9-63DDA133C9F3Q51803801-DEA13CDE-7B46-42CA-828A-D264F06E7FCCQ54186977-12320963-BF29-4B30-B026-5839322F8487Q61041081-4C5BD828-7A19-424A-9D53-0EA44AFF1B9F
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Lidia Moserle
@ast
Lidia Moserle
@en
Lidia Moserle
@es
Lidia Moserle
@nl
Lidia Moserle
@sl
type
label
Lidia Moserle
@ast
Lidia Moserle
@en
Lidia Moserle
@es
Lidia Moserle
@nl
Lidia Moserle
@sl
prefLabel
Lidia Moserle
@ast
Lidia Moserle
@en
Lidia Moserle
@es
Lidia Moserle
@nl
Lidia Moserle
@sl
P214
P1053
K-4025-2016
P106
P1153
6506896398
P21
P214
P31
P3829
P396
IT\ICCU\CFIV\257400
P496
0000-0001-9066-6786
P735
P7859
viaf-307338527